Interactive Breathing Device Found Effective In Lowering High Systolic Blood Pressure
Frost & Sullivan has awarded its 2005 Hypertension Treatment Technology Innovation of the Year Award to InterCure, Inc. for its pioneering Interactive Respiratory-Pacing technology, and in particular for its device RESPeRATE To Lower Blood Pressure® - the only FDA-cleared non-drug medical device clinically proven to lower high blood pressure. The Award has been presented at the 2nd annual Excellence in Medical Devices Awards Banquet. As over 60 million Americans suffer from hypertension and only approximately 30 percent of them successfully control their blood pressure, RESPeRATE® is expected to influence the treatment of hypertension extensively. With multiple published clinical trials and thousands of advocates, both patients and physicians, RESPeRATE® is rapidly becoming a part of the standard of care for the treatment of hypertension.

Besides being the only therapeutic self-care device treating a major cardiovascular condition, RESPeRATE® has become the first hypertension treatment available over-the-counter (OTC)."This device uses a patented interactive respiratory-pacing technology to pace a patient's breathing from the normal rate of 14 to 19 breaths/minute, to the therapeutic zone of under 10 breaths/minute," explains Frost & Sullivan research analyst Miriam Nagel. "Within minutes, muscles surrounding the small blood vessels relax to allow the blood to flow more freely, reducing high blood pressure. When used 3 to 4 times a week for as little as 15 minutes at a time, RESPeRATE® was shown to reduce high on a sustained basis by an average of 14/9 mmHg." Nagel further explains that "This battery operated device, about the size of a paperback book, takes advantage of the body's natural tendency to follow external rhythms. The RESPeRATE® kit consists of a computerized control box, a respiration sensor, and headphones. By monitoring the patient's breathing rate and pattern, the device creates a personalized melody of two distinct tones - one tone for inhalation and one for exhalation," observes Nagel.

"As patients listen to the melody and synchronize their breathing with these tones, the device gradually prolongs the exhalation tone, thereby pacing users to the slower therapeutic breathing zone."In addition to RESPeRATE® To Lower Blood Pressure, InterCure has incorporated the technology platform in a second device, InTone™, a dyspnea-improving device for patients prone to mild-to-moderate heart failure. InTone™ has been tested successfully in Phase IIa clinical trials in which it has met or exceeded primary endpoints including significant improvements in QOL (quality of life), 6-minutes walk, ejection fraction, and pulmonary artery pressure. .Frost & Sullivan presents its Technology Innovation of the Year Award to a company that has carried out new research that has resulted in innovations that have brought significant

Supplement may slow overweight kids' fat gain
NEW YORK (Reuters Health) - Supplements containing the dietary fat conjugated linoleic acid (CLA) may help overweight kids curb the amount of fat they gain over time, a small study suggests.
Taking blood pressure pills cuts risk of dying
NEW YORK (Reuters Health) - People with high blood pressure who want to reduce their risk of having a stroke or dying prematurely should get their prescriptions filled and see their doctor regularly.
Tests for genes don't predict breast cancer better
BOSTON (Reuters) - Studying genes linked to breast cancer may someday lead to better treatments, but they do little to improve a doctor's ability to predict who is likely to develop a tumor, researchers reported on Wednesday.
Supplement may slow overweight kids' fat gain
NEW YORK (Reuters Health) - Supplements containing the dietary fat conjugated linoleic acid (CLA) may help overweight kids curb the amount of fat they gain over time, a small study suggests.
Infertility treatments may raise preterm birth risk
NEW YORK (Reuters Health) - Couples who conceive through certain types of infertility treatment may have a higher-than-normal likelihood of having a premature baby, a new study suggests.
Mom's partners, discipline alters teens' drinking
NEW YORK (Reuters Health) - Young teens may be more likely to drink alcohol if their mother had multiple partners and did not consistently keep tabs on their behavior when they were 5 years old or younger, researchers from Australia found.
New attack on cancer forces cells to grow old & die
CHICAGO (Reuters) - Instead of killing off cancer cells with toxic drugs, scientists have discovered a molecular pathway that forces them to grow old and die, they said on Wednesday.
Drug-resistant TB killed 150,000 in 2008
WASHINGTON (Reuters) - Multiple drug-resistant tuberculosis killed 150,000 people in 2008 and infects between 400,000 and 500,000 people globally, according to World Health Organization estimates released on Thursday.
US budget analysts say health bill to cut deficit
WASHINGTON (Reuters) - Democrats in the House of Representatives on Thursday predicted weekend passage of a sweeping healthcare overhaul that budget analysts said would hit President Barack Obama's fiscal targets and cut the U.S. deficit over 10 years.
U.S. FDA restricts tobacco marketing to kids
WASHINGTON (Reuters) - U.S. health officials on Thursday sought to clamp down on the marketing of cigarettes to children and teenagers, issuing national limits on vending machine sales, free samples and taking other steps after a failed attempt more than a decade ago.
Child dies in Vietnam of H5N1 bird flu: paper
HANOI (Reuters) - A 3-year-old girl who lived near an illegal poultry slaughterhouse in Vietnam has died of H5N1 bird flu, state-run newspapers reported on Thursday.
Eczema drugs may need wider caution in kids: FDA staff
WASHINGTON (Reuters) - Drugs for eczema made by Novartis AG and Astellas Pharma may need their warning labels expanded after dozens of new reported cases of cancer and infection in children, U.S. Food and Drug Administration staff said in documents released on Thursday.
Anti-malaria funding must be tripled - campaigners
PARIS (Reuters) - Funding to combat malaria must be more than tripled if the mosquito-borne disease which kills nearly a million people a year is to be fought effectively, health campaigners said on Thursday.

contributions to the industry in terms of adoption, change, and competitive posture. It recognizes the quality and depth of a company's research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor in its industry.Held in San Francisco, CA., Frost & Sullivan's 2005 Excellence in Medical Devices Awards Banquet honors world-class companies for outstanding performance and achievements in the medical devices industry. About InterCure Inc.

InterCure (www.intercure.com) is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertension, heart failure, respiratory diseases and other conditions. With 7 successful clinical trials, RESPeRATE® (www.resperate.ca), InterCure's first product, became the only non-drug medical device indicated by the FDA for the adjunctive treatment of hypertension. RESPeRATE® is cleared by Health Canada and is distributed in Canada by ManthaMed Inc. Contact:Tom Kirwan 201.720.7750 x 7136e-mail protected from spam bots About ManthaMed ManthaMed is a Canadian distributor of accurate and reliable monitoring and diagnostic medical devices. Several of these leading edge medical devices are used in hospitals, physician offices and pharmacies for the diagnosis and monitoring of diseases such as diabetes, hypertension, cholesterol disorders, weight management, osteoporosis and asthma.

The company's mission is to improve patient access to early diagnosis and preventative care. More information is available at www.manthamed.com. RESPeRATE can be purchased online at www.resperate.ca. Contact: Peter Mantha 1-800-728-7327e-mail protected from spam bots About Frost & Sullivan Frost & Sullivan, a global growth consulting company founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting and training to our clients to help grow their business.

A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit www.frost.com.Contact:Stacie Jones210.247.2450e-mail protected from spam bots.